Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · individuals with sickle cell disease and a leg ulcer
It is very uncertain whether arginine butyrate plus standard care alone changes complete leg ulcer closure (defined as 100% epithelization or skin… compared with standard care alone (very low certainty).
1 finding from 1 review
Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to occurrence of new ulcer · individuals with spinal cord injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new ulcer · individuals with spinal cord injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to occurrence of new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new ulcer · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found